Is Momelotinib included in medical insurance and out-of-pocket expenses?

Momelotinib (Momelotinib) has not been officially launched in China, so it is not currently in the national medical insurance directory. For patients who want to use the drug, it can only be obtained through formal overseas channels. Due to its "unlisted" status, it cannot be reimbursed by domestic medical insurance, nor can it enter the standard medication process through the hospital's reimbursement system, which is a significant financial obstacle for patients.

In overseas markets, the original research version of molotinib is very expensive. According to the latest information, the price of the US version of molotinib is approximately more than 200,000 yuan. This price is very high for ordinary patients. Even if they use foreign pharmacies or legal cross-border medical channels, they still need to bear almost all the drug costs, causing a significant burden to patients with limited financial conditions.

However, there are currently replicas available for consideration. For example, molotinib (a generic version of Midostaurin) produced by Lucius has been approved by the Lao health department. This version has almost the same ingredients as the original drug, making it a more economical alternative. According to the current public quotation, the price of 100 mg × 30 tablets is approximately RMB 2,000. This price is very favorable compared with the original version, which can greatly reduce the financial pressure on patients, but it is necessary to pay attention to the legality of import channels and drug quality assurance.

Since molotinib is not currently covered by domestic medical insurance, patients should also bear other related costs when taking it, such as international transportation costs, import duties, customs clearance fees, and possible medical service costs (such as diagnosis, monitoring, adverse reaction treatment, etc.). Before deciding to use it, it is recommended that patients communicate with professional medical teams (doctors, pharmacists, international medical service agencies) to understand the risks and costs of different channels, and make economic plans for long-term treatment.

Reference materials:https://www.drugs.com/